MCID: LYM118
MIFTS: 69

Lymphoma malady

Categories: Cancer diseases, Immune diseases, Neuronal diseases, Eye diseases

Aliases & Classifications for Lymphoma

Summaries for Lymphoma

MedlinePlus : 41 lymphoma is a cancer of a part of the immune system called the lymph system. there are many types of lymphoma. one type is hodgkin disease. the rest are called non-hodgkin lymphomas. non-hodgkin lymphomas begin when a type of white blood cell, called a t cell or b cell, becomes abnormal. the cell divides again and again, making more and more abnormal cells. these abnormal cells can spread to almost any other part of the body. most of the time, doctors don't know why a person gets non-hodgkin lymphoma. you are at increased risk if you have a weakened immune system or have certain types of infections. non-hodgkin lymphoma can cause many symptoms, such as swollen, painless lymph nodes in the neck, armpits or groin unexplained weight loss fever soaking night sweats coughing, trouble breathing or chest pain weakness and tiredness that don't go away pain, swelling or a feeling of fullness in the abdomen your doctor will diagnose lymphoma with a physical exam, blood tests, a chest x-ray, and a biopsy. treatments include chemotherapy, radiation therapy, targeted therapy, biological therapy, or therapy to remove proteins from the blood. targeted therapy uses substances that attack cancer cells without harming normal cells. biologic therapy boosts your body's own ability to fight cancer. if you don't have symptoms, you may not need treatment right away. this is called watchful waiting. nih: national cancer institute

MalaCards based summary : Lymphoma, also known as lymphoid neoplasm, is related to ectodermal dysplasia and hodgkin lymphoma. An important gene associated with Lymphoma is ALK (ALK Receptor Tyrosine Kinase), and among its related pathways/superpathways are Prolactin Signaling Pathway and B cell receptor signaling pathway (KEGG). The drugs Adcetris and Arranon have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and bone, and related phenotypes are cellular and hematopoietic system

Disease Ontology : 12 A hematologic cancer that affects lymphocytes that reside in the lymphatic system and in blood-forming organs.

Wikipedia : 71 Lymphoma is a group of blood cell tumors that develop from lymphocytes (a type of white blood cell). The... more...

Related Diseases for Lymphoma

Diseases in the Lymphoma family:

Adult Lymphoma Eye Lymphoma

Diseases related to Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1264)
id Related Disease Score Top Affiliating Genes
1 ectodermal dysplasia 29.3 ALK BCL10 BCL2 BCL6 CCND1 MALT1
2 hodgkin lymphoma 12.4
3 burkitt lymphoma 12.3
4 follicular lymphoma 12.3
5 primary central nervous system lymphoma 12.3
6 mantle cell lymphoma 12.3
7 anaplastic large cell lymphoma 12.3
8 diffuse large b-cell lymphoma 12.3
9 lymphoma, non-hodgkin 12.3
10 lymphoma, malt, somatic 12.2
11 plasmablastic lymphoma 12.2
12 b-cell lymphomas 12.2
13 gray zone lymphoma 12.2
14 gastric lymphoma 12.2
15 thyroid lymphoma 12.2
16 primary effusion lymphoma 12.2
17 lymphoblastic lymphoma 12.1
18 intraocular lymphoma 12.1
19 extranodal nasal nk/t cell lymphoma 12.1
20 myeloid and lymphoid neoplasms associated with pdgfra rearrangement 12.1
21 splenic marginal zone lymphoma 12.1
22 cutaneous t cell lymphoma 12.1
23 marginal zone b-cell lymphoma 12.1
24 myeloid and lymphoid neoplasms associated with fgfr1 abnormalities 12.1
25 myeloid and lymphoid neoplasms with eosinophilia and abnormalities of pdgfra, pdgfrb, and fgfr1 12.1
26 primary cutaneous follicle center lymphoma 12.1
27 follicular lymphoma 1 12.0
28 composite lymphoma 12.0
29 central nervous system lymphoma 12.0
30 lymphoplasmacytic lymphoma 12.0
31 orbital lymphoma 12.0
32 bone lymphoma 12.0
33 peripheral t-cell lymphoma 11.9
34 hepatosplenic t-cell lymphoma 11.9
35 angioimmunoblastic t-cell lymphoma 11.9
36 enteropathy-associated t-cell lymphoma 11.9
37 primary mediastinal large b-cell lymphoma 11.9
38 alk-positive anaplastic large cell lymphoma 11.9
39 subcutaneous panniculitis-like t-cell lymphoma 11.9
40 myeloid and lymphoid neoplasm with fgfr1 abnormalities 11.9
41 alk-negative anaplastic large cell lymphoma 11.9
42 adult t-cell leukemia 11.9
43 intravascular large b-cell lymphoma 11.8
44 t-cell/histiocyte rich large b cell lymphoma 11.8
45 nodular lymphocyte predominant hodgkin lymphoma 11.8
46 alk-positive large b-cell lymphoma 11.8
47 primary cutaneous peripheral t-cell lymphoma not otherwise specified 11.8
48 primary cutaneous aggressive epidermotropic cd8+ t-cell lymphoma 11.8
49 splenic diffuse red pulp small b-cell lymphoma 11.8
50 primary bone lymphoma 11.8

Graphical network of the top 20 diseases related to Lymphoma:



Diseases related to Lymphoma

Symptoms & Phenotypes for Lymphoma

MGI Mouse Phenotypes related to Lymphoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.06 BCL2 BCL6 CCND1 CXCR5 MYC NPM1
2 hematopoietic system MP:0005397 9.93 MALT1 MYC NPM1 BAX BCL10 BCL11A
3 endocrine/exocrine gland MP:0005379 9.91 ALK BAX BCL10 BCL11A BCL11B BCL2
4 immune system MP:0005387 9.73 BAX BCL10 BCL11A BCL11B BCL2 BCL3
5 neoplasm MP:0002006 9.23 ALK BAX BCL11B BCL2 CCND1 MYC

Drugs & Therapeutics for Lymphoma

FDA approved drugs:

(show all 27)
id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Adcetris 17 46 BRENTUXIMAB VEDOTIN Seattle Genetics Approved August 2011
2
Arranon 17 46 NELARABINE GlaxoSmithKline Approved October 2005
3
Arzerra 17 46 OFATUMUMAB GlaxoSmithKline Approved October 2009
4
Beleodaq 17 46 BELINOSTAT Spectrum Pharmaceuticals Approved July 2014
5
Bexxar 17 46 TOSITUMOMAB; IODINE I 131 TOSITUMOMAB Corixa Approved June 2003
6
Busulfex 17 46 BUSULFAN Orphan Medical Approved February 1999
7
Elitek 17 46 RASBURICASE sanofi-aventis Approved October 2009
8
Elliotts B Solution 17 CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE Orphan Medical Approved October 1996
9
Folotyn 17 46 PRALATREXATE Allos Therapeutics Approved September 2009
10
Imbruvica 17 46 IBRUTINIB Pharmacyclics Approved November of 2013/Approved February 2014
11
Intron A 17 46 INTERFERON ALFA-2B Schering-Plough Approved December 1997/ Approved December 1995/ Approved March 1997
12
Istodax 17 46 ROMIDEPSIN Gloucester Pharmaceuticals Approved November 2009
13
Kyprolis 17 46 CARFILZOMIB Onyx Pharmaceuticals Approved July 2012
14
Mozobil 17 46 PLERIXAFOR Genzyme Approved December 2008
15
Neumega 17 OPRELVEKIN Genetics Institute Approved November 1997
16
Revlimid 17 46 LENALIDOMIDE Celgene Approved June 2013
17
Rituxan 17 46 RITUXIMAB Biogen IDEC, Genentech Approved November 1997
18
Targretin 17 46 bexarotene VALEANT LUXEMBOURG 12/29/1999
19
Treanda 17 46 BENDAMUSTINE HYDROCHLORIDE Cephalon Approved October 2008
20
UVADEX 17 METHOXSALEN Therakos Approved February 1999
21
Valchlor 17 MECHLORETHAMINE HYDROCHLORIDE Ceptaris Therapeutics Approved August 2013
22
Velcade 17 46 BORTEZOMIB Millennium Pharmaceuticals Approved May 2003
23
Xalkori 17 46 CRIZOTINIB Pfizer Approved August of 2011
24
Zevalin 17 46 IBRITUMOMAB TIUXETAN Biogen IDEC Approved February 2002
25
Zydelig 17 46 IDELALISIB Gilead Approved July 2014
26
Zykadia 17 46 CERITINIB Novartis Approved April 2014
27
Alecensa 17 ALECTINIB HYDROCHLORIDE Roche Approved December 2015

Drugs for Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 895)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 174722-31-7 10201696
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
3
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 147-94-4 6253
4
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-02-2 5743
5
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 3778-73-2 3690
6
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53-03-2 5865
7
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 2068-78-2, 57-22-7 5978
8
Aprepitant Approved, Investigational Phase 4,Phase 2,Phase 1,Early Phase 1 170729-80-3 151165 6918365
9
Fosaprepitant Approved Phase 4,Phase 2,Phase 1,Early Phase 1 172673-20-0 219090
10
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Phase 2 26787-78-0 33613 2171
11
Clarithromycin Approved Phase 4,Phase 3,Phase 2,Phase 1 81103-11-9 84029
12
Metronidazole Approved Phase 4,Phase 3,Phase 2 443-48-1 4173
13
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
14
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
15
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
16
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
17
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
18
Denileukin diftitox Approved, Investigational Phase 4,Phase 2,Phase 1 173146-27-5
19
Bexarotene Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 153559-49-0 82146
20
Asparaginase Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 9015-68-3
21
Cladribine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 4291-63-8 20279
22
Daunorubicin Approved Phase 4,Phase 3,Phase 2,Phase 1 20830-81-3 30323
23
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33419-42-0 36462
24
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1959-05-2, 59-05-2 126941
25
Thioguanine Approved Phase 4,Phase 3,Phase 2,Phase 1 154-42-7 2723601
26
Vindesine Approved Phase 4,Phase 3,Phase 2,Phase 1 59917-39-4, 53643-48-4 40839
27
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 135968-09-1
28
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
29
Vidarabine Approved Phase 4,Phase 3,Phase 2,Phase 1 24356-66-9 32326 21704
30
Entecavir Approved, Investigational Phase 4,Phase 2 142217-69-4 153941
31
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-23-7 5754 657311
32
Methoxsalen Approved Phase 4,Phase 3,Phase 2,Phase 1 298-81-7 4114
33
Melphalan Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 148-82-3 4053 460612
34
Granisetron Approved, Investigational Phase 4,Phase 2 109889-09-0 3510
35
Palonosetron Approved, Investigational Phase 4,Phase 2 135729-61-2, 119904-90-4, 135729-56-5 148211
36
Amifostine Approved, Investigational Phase 4,Phase 2,Phase 1 20537-88-6 2141
37
Thiotepa Approved Phase 4,Phase 3,Phase 2,Phase 1 52-24-4 5453
38
Busulfan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 55-98-1 2478
39
Tenofovir Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 147127-20-6 464205
40
Teniposide Approved Phase 4,Phase 3,Phase 2,Phase 1 29767-20-2 34698
41
Vinblastine Approved Phase 4,Phase 3,Phase 2,Phase 1 865-21-4 13342 241903
42
Epirubicin Approved Phase 4,Phase 3,Phase 2,Phase 1 56420-45-2 41867
43
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
44
Mechlorethamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-75-2 4033
45
Mesna Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 3375-50-6 598
46
Pegaspargase Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 130167-69-0
47
Bleomycin Approved Phase 4,Phase 3,Phase 2,Phase 1 11056-06-7 5360373
48
Dacarbazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 4342-03-4 5351166
49
Iron Approved Phase 4,Phase 3,Phase 1,Phase 2 7439-89-6 23925
50
Menthol Approved Phase 4,Phase 3,Phase 1,Phase 2 2216-51-5 16666

Interventional clinical trials:

(show top 50) (show all 5000)
id Name Status NCT ID Phase
1 Lymphoma in the Orbit Unknown status NCT01302912 Phase 4
2 Treatment of Good Prognosis, BCL-6 Negative Diffuse Large Cell Lymphoma With CHOP-R in Patients < 61 Years Old. Unknown status NCT00429065 Phase 4
3 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4
4 Optimization of the Primary Therapy for Patients With Hodgkin's Disease and Evaluation of PET Unknown status NCT00188149 Phase 4
5 Self-control Trial to Evaluate the Role of Aprepitant in the Prophylaxis of Post-lumbar-punture-headache (PLPH) Unknown status NCT02347878 Phase 4
6 Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice Unknown status NCT01273441 Phase 4
7 An Observational Study of Lymphoma in Patients With Rheumatoid Arthritis or Crohn's Disease. Completed NCT00440817 Phase 4
8 Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin America Completed NCT02559583 Phase 4
9 Observational Study on the Occurrence of Hepatosplenic T-cell Lymphoma in Patients of Netherlands Completed NCT00731536 Phase 4
10 Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin’s Lymphoma Completed NCT00168727 Phase 4
11 Treatment of Peripheral T-cell Lymphoma Completed NCT01664975 Phase 4
12 Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL) Completed NCT00211198 Phase 4
13 PEG-rhG-CSF in Patients With Lymphoma Receiving Chemotherapy Completed NCT02805218 Phase 4
14 Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL) Completed NCT01007448 Phase 4
15 MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma. Completed NCT00430352 Phase 4
16 German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults Completed NCT00199017 Phase 4
17 Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma Completed NCT00969462 Phase 4
18 Hepatitis B Virus Reactivation After Withdrawal of Prophylactic Antiviral Therapy in Lymphoma Patients Completed NCT02108444 Phase 4
19 Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms Completed NCT01164475 Phase 4
20 Whole Brain Irradiation in Primary Central Nervous System (CNS) Lymphoma (PCNSL) Completed NCT00153530 Phase 4
21 Efficacy Response Duration and Toxicity of Rituximab, Fludarabine, and Cyclophosphamide (RFC) as 1st Line Treatment and Rituximab (R) in Maintenance Treatment in Follicular Non Hodgkin (FNH) Lymphoma Completed NCT01124526 Phase 4
22 Prophylactic Use of Entecavir for Non-Hodgkin's Lymphoma Patients With Resolved Hepatitis B Completed NCT00926757 Phase 4
23 Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients Completed NCT00050999 Phase 4
24 An Expanded Access Program of Pegfilgrastim (Neulastim) in Participants With Non-Hodgkin's Lymphoma (NHL) Completed NCT02782845 Phase 4
25 LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV) Completed NCT00466258 Phase 4
26 Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients Completed NCT00051012 Phase 4
27 Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma Completed NCT00090038 Phase 4
28 Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy Completed NCT00230217 Phase 4
29 Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-grade Lymphoma in Adults Completed NCT00199082 Phase 4
30 Prevention of CHOP-induced Chronic Cardiotoxicity Completed NCT00162955 Phase 4
31 Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A Completed NCT00221039 Phase 4
32 Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab) Completed NCT01418430 Phase 4
33 PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation Completed NCT00352703 Phase 4
34 Epoetin Alfa (Hemax®) Phase IV Study in Chemotherapy Induced Anemia Completed NCT01374373 Phase 4
35 Effect of Epoetin Alfa on Hemoglobin, Symptom Distress, and Quality of Life in Patients Receiving Chemotherapy Completed NCT00524407 Phase 4
36 Evaluation of the Analgesy With Emla and/or Nitrous Oxide in Pediatric Patients for Lumbar Puncture Completed NCT00808171 Phase 4
37 ALL-REZ BFM 2002: Multi-Center Study for Children With Relapsed Acute Lymphoblastic Leukemia Completed NCT00114348 Phase 4
38 DepoCyt Therapy in Patients With Neoplastic Meningitis From Lymphoma or a Solid Tumor Completed NCT00029523 Phase 4
39 AMENO-2: Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors Completed NCT00415103 Phase 4
40 Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation Completed NCT01339572 Phase 4
41 Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients Completed NCT00195533 Phase 4
42 A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer Completed NCT00277160 Phase 4
43 Subcutaneous Amifostine Safety Study Completed NCT00158041 Phase 4
44 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4
45 Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT) Completed NCT00361140 Phase 4
46 Registry of Patients Treated With Plerixafor (Mozobil®) for Haematopoietic Stem Cell Mobilization Before Autologous Transplantation Completed NCT01738373 Phase 4
47 Conventional Versus Ultrasound-guided Transbronchial Needle Aspiration for the Diagnosis of Hilar/Mediastinal Lymphadenopathies Completed NCT01658280 Phase 4
48 LAL-BR/2001: Study Treatment to Low Risk ALL Completed NCT00526175 Phase 4
49 The Study on the Pharmacokinetics of PEG-rhG-CSF in Children and Adolescents Completed NCT02953730 Phase 4
50 To Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma Recruiting NCT02585947 Phase 4

Search NIH Clinical Center for Lymphoma

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: lymphoma

Genetic Tests for Lymphoma

Genetic tests related to Lymphoma:

id Genetic test Affiliating Genes
1 Lymphoma 29

Anatomical Context for Lymphoma

MalaCards organs/tissues related to Lymphoma:

39
B Cells, T Cells, Bone, Breast, Thyroid, Bone Marrow, Skin

Publications for Lymphoma

Articles related to Lymphoma:

(show top 50) (show all 22276)
id Title Authors Year
1
ZDHHC11 and ZDHHC11B are critical novel components of the oncogenic MYC-miR-150-MYB network in Burkitt lymphoma. ( 28331227 )
2017
2
Recommendations for Clinical Trial Development in Mantle Cell Lymphoma. ( 28040733 )
2017
3
Correlation of Patterns of Bone Marrow Infiltration and Biochemical factors in Non-Hodgkin Lymphoma. ( 28523057 )
2017
4
Acute myelitis resembling human T-lymphotropic virus type 1-associated myelopathy presenting as high-signal-intensity long cord lesions on T2-weighted magnetic resonance images combined with lymphoma-type adult T-cell leukemia/lymphoma. ( 27817856 )
2017
5
Erythema multiforme-like cutaneous lesions in monomorphic epitheliotropic intestinal T-cell lymphoma: a rare case report. ( 27862162 )
2017
6
Gastrointestinal mantle cell lymphoma with isolated mass and multiple lymphomatous polyposis: report of two cases. ( 28451951 )
2017
7
SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma. ( 28533307 )
2017
8
Using Health Care Claims Data to Assess the Prevalence of Hodgkin Lymphoma and Relapsed or Refractory Hodgkin Lymphoma in the United States. ( 28065438 )
2017
9
A Comprehensive Assessment of Toxicities in Patients with Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using Thiotepa, Busulfan, and Cyclophosphamide Conditioning. ( 27713090 )
2017
10
Novel agents in mantle cell lymphoma. ( 28480764 )
2017
11
Juvenile dermatomyositis/polymyositis and lymphoma. ( 28477693 )
2017
12
Hematopoeitic stem cell transplantation for adult T cell leukemia-lymphoma: Who is the best candidate? ( 27786571 )
2017
13
Imaging of Early Response to Predict Prognosis in the First-Line Management of Follicular Non-Hodgkin Lymphoma with Iodine-131-Rituximab Radioimmunotherapy. ( 28498337 )
2017
14
Dismal outcome of allogeneic hematopoietic stem cell transplantation for relapsed adult T-cell leukemia/lymphoma, a Japanese nation-wide study. ( 28067877 )
2017
15
The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma. ( 28403071 )
2017
16
B-cell lymphomas involving Waldeyer's ring characterized by distinctive clinical and histopathological features: a comparison of pediatric to adult patients. ( 28086220 )
2017
17
Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma. ( 28416797 )
2017
18
CD8+ T-cell-mediated Interface Dermatitis after CCR4+ T-cell Depletion by Mogamulizumab Treatment of Adult T-cell Leukaemia/lymphoma. ( 27786349 )
2017
19
The prognostic value of clonal heterogeneity and quantitative assessment of plasma circulating clonal IG-VDJ sequences at diagnosis in patients with follicular lymphoma. ( 28060738 )
2017
20
Erratum to: Role of PET/CT in malignant pediatric lymphoma. ( 28058463 )
2017
21
Primary Burkitt lymphoma of the supraglottic larynx: a case report and review of the literature. ( 28279203 )
2017
22
Gemcitabine, dexamethasone, and cisplatin (GDP) as salvage chemotherapy for patients with relapsed or refractory peripheral T cell lymphoma-not otherwise specified. ( 27858107 )
2017
23
Approach to the diagnosis and treatment of high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements. ( 27821509 )
2017
24
Cyclin D1-negative blastoid mantle cell lymphoma exhibiting cleaved to bilobated cytomorphology. ( 28495928 )
2017
25
Comprehensive Transcriptome and Mutational Profiling of Endemic Burkitt Lymphoma Reveals EBV Type-Specific Differences. ( 28465297 )
2017
26
Using Murine Models to Investigate Tumor-Lymphoid Interactions: Spotlight on Chronic Lymphocytic Leukemia and Angioimmunoblastic T-Cell Lymphoma. ( 28512625 )
2017
27
Chemotherapy Response Assessment by FDG-PET-CT in Early-stage Classical Hodgkin Lymphoma: Moving Beyond the Five-Point Deauville Score. ( 28068241 )
2017
28
Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations. ( 28040700 )
2017
29
Mathematical model of T-cell lymphoblastic lymphoma: disease, treatment, cure or relapse of a virtual cohort of patients. ( 28082512 )
2017
30
High grade follicular lymphoma in a patient receiving adalimumab and methotrexate for pityriasis rubra pilaris. ( 28266882 )
2017
31
Mantle cell lymphoma with central nervous system involvement simulating bilateral subdural hematomas. ( 28063897 )
2017
32
Comparative genomic expression signatures of signal transduction pathways and targets in paediatric Burkitt lymphoma: a Children's Oncology Group report. ( 28474336 )
2017
33
TET2 mutation in diffuse large B-cell lymphoma. ( 28331128 )
2017
34
B-cell lymphoma 2 inhibitor ABT-737 induces Beclin1- and reactive oxygen species-dependent autophagy in Adriamycin-resistant human hepatocellular carcinoma cells. ( 28351336 )
2017
35
Synchronous T lymphoblastic lymphoma and myeloid neoplasm with PDGFRA rearrangement. ( 28013529 )
2017
36
A specific mode of microsatellite instability is a crucial biomarker in adult T-cell leukaemia/lymphoma patients. ( 27783137 )
2017
37
Possible Interaction Between Cigarette Smoking and HLA-DRB1 Variation in the Risk of Follicular Lymphoma. ( 28369180 )
2017
38
Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group. ( 28041583 )
2017
39
Prognostic Impact of MUM1/IRF4 Expression in Burkitt Lymphoma (BL): A Reappraisal of 88 BL Patients in Japan. ( 28079574 )
2017
40
The effects of DLEU1 gene expression in Burkitt lymphoma (BL): potential mechanism of chemoimmunotherapy resistance in BL. ( 28427156 )
2017
41
Mutation analysis of tumor necrosis factor alpha-induced protein 3 gene in Hodgkin lymphoma. ( 28189285 )
2017
42
Associations between genetic variants in immunoregulatory genes and risk of non-Hodgkin lymphoma in a Chinese population. ( 28060727 )
2017
43
Second-line rituximab, lenalidomide, and bendamustine (R2B) in mantle cell lymphoma: a phase 2 clinical trial of the Fondazione Italiana Linfomi. ( 28082342 )
2017
44
Frondoside A induces AIF-associated caspase-independent apoptosis in Burkitt lymphoma cells. ( 28508718 )
2017
45
Dietary inflammatory index and non-Hodgkin lymphoma risk in an Italian case-control study. ( 28503716 )
2017
46
Recommendations for Clinical Trial Development in Follicular Lymphoma. ( 28040699 )
2017
47
Silencing of CKIP-1 promotes tumor proliferation and cell adhesion-mediated drug resistance via regulating AKT activity in non-Hodgkin's lymphoma. ( 27840970 )
2017
48
Mantle Cell Lymphoma: Contemporary Diagnostic and Treatment Perspectives in the Age of Personalized Medicine. ( 28404221 )
2017
49
SOX-11 detection in decalcified bone marrow tissue in mantle cell lymphoma patients, methodological issue on reproducibility and validity. ( 28457728 )
2017
50
Genetic inhibition of Anaplastic Lymphoma Kinase rescues cognitive impairments in Neurofibromatosis 1 mutant mice. ( 28057529 )
2017